Posted by Michael Wonder on 03 Oct 2018
EU nod for Lilly’s new breast cancer drug
3 October 2018 - Eli Lilly’s CDK 4 and 6 inhibitor Verzenios has been approved in Europe for the treatment of certain metastatic breast cancers.
The decision gives doctors the green light to prescribe the drug for women with hormone receptor-positive, epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
The applications were based on the Phase III MONARCH 2 and 3 trials.
